Gary Titus Insider Profile

4 Followers
Gary Titus, Director at ImmunoCellular Therapeutics, holds 28.00K shares in ImmunoCellular Therapeutics (Ticker: IMUC), holds 37.09K shares in Sciclone Pharmaceuticals (Ticker: SCLN), holds 2.63K shares in Oruka Therapeutics (Ticker: ORKA).
tipranks
Gary Titus

Gary Titus
ImmunoCellular Therapeutics (IMUC)
Director

Ranked #7,895 out of 99,218 Corporate Insiders

Profitable Transactions

83%
5 out of 6 Profitable Transactions

Average Return

+35.60%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$73K
95.62%
4.38%
A breakdown of Gary Titus's holdings

Insider Roles

Oruka Therapeutics
(ORKA)
Chief Acct.Officer
ImmunoCellular Therapeutics
(IMUC)
Director
Roles that Gary Titus holds in companies

Most Profitable Insider Trade

Stock:
Sciclone Pharmaceuticals
(SCLN)
Rating:Informative Buy
Date:May 26, 2009 - May 26, 2010
Return:+69.50%
The most profitable trade made by Gary Titus

Gary Titus's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
ImmunoCellular Therapeutics
Sep 22, 2015
Director
Uninformative Buy
$3.22K
SCLN
Sciclone Pharmaceuticals
Jun 18, 2012
Uninformative Buy
1.00K
$413.61K
Oruka Therapeutics
Chief Acct.Officer
$70.25K
List of latest transactions for each holding click on a transaction to see Gary Titus's performance on stock

Gary Titus insider profile FAQ

What is the percentage of profitable transactions made by Gary Titus?
The percentage of profitable transactions made by Gary Titus is 83%.
    What is the average return per transaction made by Gary Titus?
    The average return per transaction made by Gary Titus is 35.60%.
      What stocks does Gary Titus hold?
      Gary Titus holds: IMUC, SCLN, ORKA stocks.
        What was Gary Titus’s latest transaction?
        Gary Titus latest transaction was an Uninformative Buy of ―.
          What was Gary Titus's most profitable transaction?
          Gary Titus’s most profitable transaction was an Informative Buy of SCLN stock on May 26, 2009. The return on the trade was 69.50%.
            What is Gary Titus's role in ImmunoCellular Therapeutics?
            Gary Titus's role in ImmunoCellular Therapeutics is Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.